Phase I Trial of (90)Y-DOTA(0)-Tyr(3)-Octreotide Therapy in Children and Young Adults with Refractory Solid Tumors That Express Somatostatin Receptors

PURPOSE: Conduct a Phase I trial of (90)Y-DOTA(0)-Tyr(3)-octreotide to determine the dose/toxicity profile in children and young adults with somatostatin receptor positive tumors. METHODS: A 3×3 design was utilized to determine the highest tolerable dose of (90)Y-DOTA(0)-Tyr(3)-octreotide with admin...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Menda, Yusuf, Sue O’Dorisio, M., Kao, Simon, Khanna, Geetika, Michael, Stacy, Connolly, Mary, Babich, John, O’Dorisio, Thomas, Bushnell, David, Madsen, Mark
Formato: Artigo
Lenguaje:Inglês
Publicado: 2010
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3753801/
https://ncbi.nlm.nih.gov/pubmed/20847174
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.110.075226
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares